A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study
Published in
The American journal of gastroenterology, vol. 102, no. 7, p. 1397-1405Publication date
2007Abstract
Keywords
- Adult
- Aged
- Biological Markers/blood
- Biopsy
- Delayed-Action Preparations
- Double-Blind Method
- Endothelin-1/blood
- Female
- Follow-Up Studies
- Gastrointestinal Agents/administration & dosage/pharmacokinetics
- Humans
- Hypertension, Portal/drug therapy/etiology/physiopathology
- Immunoenzyme Techniques
- Injections, Intramuscular
- Liver Cirrhosis/blood/complications/pathology
- Male
- Middle Aged
- Octreotide/administration & dosage/pharmacokinetics
- Portal Pressure/physiology
- Radioimmunoassay
- Retrospective Studies
- Time Factors
- Treatment Outcome
- Urotensins/blood
- Vascular Endothelial Growth Factor A/blood
UNIGE affiliation entities
UNIGE research groups
Citation (ISO format)
SPAHR, Laurent François Joséph et al. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. In: The American journal of gastroenterology, 2007, vol. 102, n° 7, p. 1397–1405. doi: 10.1111/j.1572-0241.2007.01262.x
Main files (1)
Article (Published version)
Identifiers
- PID : unige:35201
- DOI : 10.1111/j.1572-0241.2007.01262.x
- PMID : 17488248
